Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | AML: mutant IDH1 inhibitor HMS-101

Michael Heuser • 25 Oct 2019
COSTEM 2019
Acute Myeloid Leukemia Leukemia HMS-101

Michael Heuser, MD, Hannover Medical School, Hannover, Germany, discusses the aims, methods and findings of his study of the in vivo efficacy of the mutant IDH1 inhibitor HMS-101 and the structural resolution of a distinct binding site. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Michael Heuser

BAY1436032: IDH1 inhibition in IDH1-mutated AML
3:01
BAY1436032: IDH1 inhibition in IDH1-mutated AML
Michael Heuser • 2 Jun 2020
Final results of BRIGHT AML 1003
3:13
Final results of BRIGHT AML 1003
Michael Heuser • 12 Jun 2020
Is MRD monitoring prior to allograft standard in AML?
3:13
Is MRD monitoring prior to allograft standard in AML?
Michael Heuser • 25 Oct 2019
The clinical application of MRD testing in AML
1:30
The clinical application of MRD testing in AML
Michael Heuser • 1 Jun 2019

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals